CURE Pharmaceutical Joins Cannabis Market

- May 11th, 2017

CURE Pharmaceutical announced it has decided to enter the cannabis sector with resources going towards the research on the medical use of cannabinoids.

CURE Pharmaceutical (OTCQB:CURR) announced it has decided to enter the cannabis sector with resources going towards the research on the medical use of cannabinoids.
As quoted in the press release:

CURE has developed a pharmaceutical cannabinoid division to research and develop clinically ready cannabinoid drug formulations and delivery systems for both human and/or animal patients and is developing a global footprint with partners in the U.S., Canada, Israel and Germany, among other markets. The Company has taken a leadership role in optimizing plant base cannabinoids by vertically integrating drug discovery, proprietary extraction technology, genetic-specific cannabinoids research, and drug development.
“We are well-positioned in the pharmaceutical cannabis sector and excited to work within an industry with such a promising future,” said Rob Davidson, CEO of CURE. “Our goal is to bring new cannabinoid molecules to the market through the FDA regulatory process, while utilizing our company’s proprietary delivery technologies to increase efficacy, as well as target unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options.”
CURE is researching and developing proprietary formulas of different cannabinoids and terpene profiles integrated into its advanced oral thin film, CureFilm™ and transdermal applications leveraging its proprietary polymer and encapsulation technology. The Company is focusing on integrating its proprietary delivery systems to provide solutions to conditions like pain, neuropathy, cancer (including pediatric cancer), PTSD and other psychiatric disorders, autoimmune diseases, Parkinson’s disease and sleep disorders.

Click here to read the full press release.

Source: globenewswire.com

Get the latest Cannabis Investing stock information

Leave a Reply